According to an article in Medscape Medical News, a study presented at the AACE 2025 conference indicates that individuals treated for obesity using semaglutide (Wegovy) may experience a significantly lower risk of fractures compared to those who undergo sleeve gastrectomy. Researchers utilized electronic health record data and observed a 26% reduction in fracture risk for the semaglutide group over a three-year period. The study authors hypothesize that GLP-1 agonists like semaglutide may have protective mechanisms for bone health that warrant further investigation, contrasting with the known decrease in bone density associated with bariatric surgery. While this initial data is promising, additional studies are needed to fully understand the correlation and consider other influencing factors.
Audio Overview (Google NotebookLM)
(12 minutes 5 seconds)
